Company Overview
Advanced Cell Technology, Inc. (OTCBB:ACTC – News) is a biotechnology company that specializes in the development of cellular therapies for the treatment of rare and common diseases that impact millions of people worldwide. The company applies stem cell-based technologies and other proprietary methods in the area of regenerative medicine to bring patient-specific therapies from the lab to the bedside.
In support of its research and applications Advanced Cell owns or licenses over 380 patents and patent applications.
We are currently focused on three product areas.
1) Our retinal pigment epithelium (RPE) program , which we believe will yield new therapies for treating disease indications and disorders such as age-related macular degeneration (AMD).
2) Our hemangioblast (HG) cell program which could yield novel therapies for cardiac diseases such as heart failure has successfully completed Phase I human clinical trials.
3) Our myoblast program , which could yield novel therapies for cardiac diseases such as heart failure has successfully completed Phase I human clinical trials.
Advanced Cell is led by an experienced management team and world-class scientific team, including CEO William Caldwell, Chief Scientific Officer Robert Lanza M.D., VP of Regulatory Ed Mickunas, Senior Director of Manufacturing Roger Gay PhD and our Director of Operations Rita Parker. The company operates a GMP-capable laboratory in Massachusetts and maintains offices in Southern California.
The company is actively pursuing strategic collaborations in the United States (e.g., in California, where in 2004, the state passed Proposition 71, often referred to as the “Stem Cell Initiative,” which will provide $3.0 billion of funding over the next ten years for stem cell research) and around the world with members of academia, industry and foundations to further accelerate the pace of our research efforts.
Specialties
biotechnology, regenerative medicine
